FIG 2.

PFS based on sustained MRD negativity (10⁻⁵; ≥ 6 months) in the ITT populations of POLLUX (A) and CASTOR (B). Shown are the results of the Kaplan-Meier estimates of PFS among patients in the ITT population based on sustained MRD negativity ≥ 6 months at a threshold of one tumor cell per 10⁵ white cells. Blue lines show regimens containing daratumumab; red lines show standard-of-care regimens. D-Rd, daratumumab plus lenalidomide and dexamethasone; D-Vd, daratumumab plus bortezomib and dexamethasone; ITT, intention-to-treat; MRD, minimal residual disease; PFS, progression-free survival; Rd, lenalidomide and dexamethasone; Vd, bortezomib and dexamethasone.